Niacin Supplements Explained: Benefits, Dose, Risks, and Evidence

Government and public-health guidance consistently present niacin’s most established role as prevention and treatment of deficiency, especially pellagra. WHO specifically recommends nicotinamide, usually 300 mg daily in divided doses for 3 to 4 weeks, because it treats pellagra without the intense flushing seen with nicotinic acid. NIH ODS — Niacin Fact Sheet; WHO — Pellagra and Its Prevention and Control.

A Cochrane review covering more than 35,000 participants found that niacin did not reduce overall mortality, cardiovascular mortality, myocardial infarction, or stroke. A JAMA Network Open meta-analysis reached a similar conclusion and noted that any apparent benefit was mainly driven by much older monotherapy-era trials, not modern statin-based care. Cochrane — Niacin for Cardiovascular Disease Review; PubMed — JAMA Network Open Niacin Meta-analysis.

In HPS2-THRIVE and AIM-HIGH, added niacin improved HDL and triglycerides but did not significantly improve major cardiovascular outcomes in patients already receiving effective statin therapy. Safety follow-up also showed excess serious adverse effects, including worse glycemic control, new-onset diabetes, bleeding, infection, and gastrointestinal problems. PubMed — HPS2-THRIVE Trial; PubMed — HPS2-THRIVE Safety Analysis; FDA — Extended-Release Niacin Label.

A phase 3 randomized trial found that nicotinamide 500 mg twice daily reduced new nonmelanoma skin cancers and actinic keratoses over 12 months in high-risk adults with prior skin cancers. A later systematic review and meta-analysis broadly supported this signal, although the evidence remains strongest in selected high-risk groups and during active treatment. PubMed — Phase 3 Nicotinamide Skin Cancer Trial; PubMed — Nicotinamide Skin Cancer Meta-analysis.

This belief sounded plausible for years, but modern evidence does not support it in statin-treated patients. Niacin can improve HDL and triglyceride measurements, yet large reviews and major trials show no routine reduction in cardiovascular events and more treatment-limiting side effects. Better lipid numbers are not automatically the same as better long-term clinical outcomes. Cochrane — Niacin for Cardiovascular Disease Review; PubMed — HPS2-THRIVE Trial; ADA Standards of Care — Lipid Management.

Many no-flush products contain inositol hexaniacinate or related compounds rather than the nicotinic acid used in lipid trials. That means consumers may assume they are buying a safer version of proven niacin therapy when they may actually be buying a different compound with a different evidence base and different expected effects. Harvard Health — No-Flush Niacin.

Nicotinic acid, nicotinamide, nicotinamide riboside, and related products are often marketed together, but they are not clinically identical. Nicotinamide has evidence in pellagra treatment and selected skin-cancer chemoprevention, nicotinic acid is the lipid-active flushing form, and nicotinamide riboside has mainly been evaluated as a bioavailable nicotinamide source rather than a proven substitute for classic niacin therapy. NIH ODS — Niacin Fact Sheet; EFSA — Nicotinamide Riboside Chloride Opinion.

Niacin’s core role is nutritional before it is therapeutic. It is an essential vitamin required for normal metabolism, and adult intake is expressed as niacin equivalents because the body can make niacin from tryptophan. Severe deficiency causes pellagra, a clinically important condition historically linked with poor diet, alcohol misuse, malabsorption, and certain disease states. This basic nutritional role is the most certain reason to use niacin supplementation and is more firmly established than popular claims about cholesterol or healthy aging. NIH ODS — Niacin Fact Sheet; WHO — Pellagra and Its Prevention and Control.

For confirmed or strongly suspected pellagra, WHO recommends nicotinamide rather than nicotinic acid because it avoids the intense vasodilatory flushing that can make nicotinic acid difficult to tolerate. A typical oral regimen is 300 mg per day in divided doses for 3 to 4 weeks. In public-health and clinical terms, this remains one of the least controversial applications of niacin: deficiency treatment is established, rational, and important. WHO — Pellagra and Its Prevention and Control; NIH ODS — Niacin Fact Sheet.

Form is not a minor labeling detail. Nicotinic acid is the classic flushing form and the form historically used for lipid modification. Nicotinamide, also called niacinamide, generally does not cause flushing and is preferred for pellagra treatment and the best-supported skin-cancer prevention use. The supplement market also includes inositol hexaniacinate and nicotinamide riboside, which are often grouped under the broader “vitamin B3” label even though they are not clinically interchangeable with nicotinic acid. NIH ODS — Niacin Fact Sheet; Harvard Health — No-Flush Niacin.

Mechanistic work helps explain these differences. Nicotinic acid appears to activate HCAR2/GPR109A, influencing adipose tissue lipolysis and contributing to triglyceride lowering. The same receptor pathway is linked to flushing through prostaglandin-mediated signaling in skin immune cells, which is why the form that changes lipid markers is also the form most associated with burning, itching, redness, dizziness, and sometimes hypotension. Nicotinamide does not share this classic flush profile and is not considered equivalent for lipid therapy. PubMed — HCAR2 and Niacin Mechanisms Review; FDA — Extended-Release Niacin Label; NIH ODS — Niacin Fact Sheet.

The lipid story is biologically real but clinically incomplete. Prescription extended-release niacin can reduce triglycerides, raise HDL cholesterol, and improve some other lipid parameters, and FDA labeling documents dose-response effects. Historically, that made niacin an appealing option for dyslipidemia. But lipid improvement is a surrogate marker, not the final clinical outcome that matters most to patients. FDA — Extended-Release Niacin Label; NIH ODS — Niacin Fact Sheet.

Modern cardiovascular trials changed niacin’s place in practice. The Cochrane review found no significant reduction in mortality, myocardial infarction, or stroke. HPS2-THRIVE similarly showed no major vascular-event benefit despite improved HDL and triglycerides, and AIM-HIGH reached a comparable no-benefit result summarized in prescription labeling. Current guidance therefore does not recommend niacin as a routine add-on to statins for ASCVD prevention. The key observation is not that niacin fails to change lab values, but that those changes did not reliably produce better cardiovascular outcomes in contemporary care. Cochrane — Niacin for Cardiovascular Disease Review; PubMed — HPS2-THRIVE Trial; FDA — Extended-Release Niacin Label; ADA Standards of Care — Lipid Management.

Nicotinamide has a distinct evidence profile from nicotinic acid. In high-risk adults with a prior history of nonmelanoma skin cancer, nicotinamide 500 mg twice daily reduced new nonmelanoma skin cancers and actinic keratoses during active treatment in a phase 3 trial. A later meta-analysis broadly supported this finding, although the literature is still limited and best interpreted for recurrent keratinocyte skin-cancer prevention in selected high-risk adults rather than the general public. PubMed — Phase 3 Nicotinamide Skin Cancer Trial; PubMed — Nicotinamide Skin Cancer Meta-analysis.

The benefit also appears conditional rather than universal. The trial evidence applies mainly to immunocompetent adults at high risk because of prior nonmelanoma skin cancers, and the benefit was observed during the treatment period rather than clearly persisting after supplementation stopped. The same evidence should not be generalized to melanoma prevention or to all-purpose cancer prevention. This is a useful example of why niacin research must be read by compound, dose, and population rather than by vitamin family alone. PubMed — Phase 3 Nicotinamide Skin Cancer Trial; PubMed — Nicotinamide Skin Cancer Meta-analysis.

Safety depends strongly on both dose and formulation. Immediate-release nicotinic acid tends to produce more flushing, while older sustained-release products have been linked to greater hepatotoxicity. LiverTox notes that serious liver injury has occurred, including after switching from immediate-release to sustained-release niacin at similar nominal doses. Prescription extended-release niacin is better characterized than many over-the-counter timed-release products, but it still requires monitoring and does not eliminate liver risk. LiverTox — Niacin; FDA — Extended-Release Niacin Label; NIH ODS — Niacin Fact Sheet.

The adverse-effect profile is broader than flushing. High-dose nicotinic acid can worsen glucose control, raise uric acid, contribute to gout, irritate the gastrointestinal tract, lower blood pressure, and cause ocular complications such as macular edema. A meta-analysis found roughly a one-third higher relative risk of new-onset diabetes, and HPS2-THRIVE also reported excess serious adverse effects including bleeding, infection, and GI problems. Because products differ by chemical form and release profile, label reading and product verification matter unusually much in this category. PubMed Central — Niacin and New-Onset Diabetes Meta-analysis; PubMed — HPS2-THRIVE Safety Analysis; NIH ODS — Dietary Supplement Label Database; USP — Quality and Supplements.